Clinical management of hereditary colorectal cancer syndromes

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 2, 2015, Pages 88-97

  Vasen, Hans F A ^a   Tomlinson, Ian ^b   Castells, Antoni ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; SULINDAC; TOREMIFENE;

ADENOMATOUS POLYP; APC GENE; BMPR1A GENE; CANCER RISK; CLINICAL FEATURE; COLON RESECTION; COLORECTAL CANCER; CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY; DESMOID TUMOR; DISEASE CLASSIFICATION; DISEASE COURSE; EPCAM GENE; GENE; GENE FUNCTION; GENETIC VARIABILITY; GREM1 GENE; HEREDITARY COLORECTAL CANCER; HEREDITARY MIXED POLYPOSIS SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; JUVENILE POLYPOSIS SYNDROME; MISMATCH REPAIR; MLH1 GENE; MSH2 GENE; MSH6 GENE; MUTYH GENE; MUTYH POLYPOSIS; PEUTZ JEGHERS SYNDROME; PMS2 GENE; POLD1 GENE; POLE GENE; POLYPOSIS; PRIORITY JOURNAL; PROCTOCOLECTOMY; PTEN GENE; PTEN HAMARTOMA SYNDROME; REVIEW; SERRATED POLYPOSIS; SIGMOIDOSCOPY; SMAD4 GENE; STK11 GENE; ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; EARLY DIAGNOSIS; GENETICS; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PROCEDURES;

ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; EARLY DETECTION OF CANCER; HUMANS; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY;

EID: 84926127367     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.229     Document Type: Review

References (84)

1. Lynch, H. T. & de la Chapelle, A. Hereditary colorectal cancer. N. Engl. J. Med. 348, 919-932 (2003).
2. Vasen, H. F. et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57, 704-713 (2008).
3. Nieuwenhuis, M. H. et al. Genotype predicting phenotype in familial adenomatous polyposis: a practical application to the choice of surgery. Dis. Colon Rectum 52, 1259-1263 (2009).
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal. version 2.2014 [online], https://www.nccn.org/store/login/login.aspx? ReturnURL=http://www.nccn.org/professionals/physician-gls/pdf/genetics-colon.pdf (2014).
5. Giardiello, F. M. et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med. 346, 1054-1059 (2002).
6. Phillips, R. K. et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50, 857-860 (2002).
7. Barrow, P., Khan, M., Lalloo, F., Evans, D. G. & Hill, J. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br. J. Surg. 100, 1719-1731 (2013).
8. Belchetz, L. A., Berk, T., Bapat, B. V., Cohen, Z. & Gallinger, S. Changing causes of mortality in patients with familial adenomatous polyposis. Dis. Colon Rectum 39, 384-387 (1996).
9. Nieuwenhuis, M. H. et al. Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br. J. Cancer 104, 37-42 (2011).
10. Fallen, T., Wilson, M., Morlan, B. & Lindor, N. M. Desmoid tumors-a characterization of patients seen at Mayo Clinic 1976-1999. Fam. Cancer 5, 191-194 (2006).
11. Hansmann, A., Adolph, C., Vogel, T., Unger, A. & Moeslein, G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 100, 612-620 (2004).
12. Nielsen, M., Morreau, H., Vasen, H. F. & Hes, F. J. MUTYH-associated polyposis (MAP). Crit. Rev. Oncol. Hematol. 79, 1-16 (2011).
13. Sampson, J. R. & Jones, N. MUTYH-associated polyposis. Best Pract. Res. Clin. Gastroenterol. 23, 209-218 (2009).
14. Boparai, K. S. et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology 135, 2014-2018 (2008).
15. Vogt, S. et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 137, 1976-1985 (2009).
16. Theodoratou, E. et al. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br. J. Cancer 103, 1875-1884 (2010).
17. Palles, C. et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45, 136-144 (2013).
18. Valle, L. et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum. Mol. Genet. 23, 3506-3512 (2014).
19. Elsayed, F. A. et al. Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. Eur. J. Hum. Genet. http://dx.doi.org/10.1038/ejhg.2014.242.
20. Wimmer, K. & Etzler, J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum. Genet. 124, 105-122 (2008).
21. Wimmer, K. et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD). J. Med. Genet. 51, 355-365 (2014).
22. Vasen, H. F. et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium "Care for CMMR-D" (C4CMMR-D). J. Med. Genet. 51, 283-293 (2014).
23. Hes, F. J. et al. Colorectal cancer risk variants on 11q23 and 15q13 are associated with unexplained adenomatous polyposis. J. Med. Genet. 51, 55-60 (2014).
24. Beggs, A. D. et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 59, 975-986 (2010).
25. van Lier, M. G., Mathus-Vliegen, E. M., Wagner, A., van Leerdam, M. E. & Kuipers, E. J. High cumulative risk of intussusception in patients with Peutz-Jeghers syndrome: time to update surveillance guidelines? Am. J. Gastroenterol. 106, 940-945 (2011).
26. van Lier, M. G. et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am. J. Gastroenterol. 105, 1258-1264 (2010).
27. Kara, C., Kutlu, A. O., Tosun, M. S., Apaydin, S. & Senel, F. Sertoli cell tumor causing prepubertal gynecomastia in a boy with Peutz-Jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone. Horm. Res. 63, 252-256 (2005).
28. Gammon, A., Jasperson, K., Kohlmann, W. & Burt, R. W. Hamartomatous polyposis syndromes. Best Pract. Res. Clin. Gastroenterol. 23, 219-231 (2009).
29. Brosens, L. A. et al. Gastrointestinal polyposis syndromes. Curr. Mol. Med. 7, 29-46 (2007).
30. Howe, J. R. et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J. Med. Genet. 41, 484-491 (2004).
31. Brosens, L. A. et al. Risk of colorectal cancer in juvenile polyposis. Gut 56, 965-967 (2007).
32. Friedl, W. et al. Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers. Hum. Genet. 111, 108-111 (2002).
33. Schwenter, F. et al. Juvenile polyposis, hereditary hemorrhagic telangiectasia, and early onset colorectal cancer in patients with SMAD4 mutation. J. Gastroenterol. 47, 795-804 (2012).
34. Howe, J. R., Ringold, J. C., Hughes, J. H. & Summers, R. W. Direct genetic testing for Smad4 mutations in patients at risk for juvenile polyposis. Surgery 126, 162-170 (1999).
35. Nieuwenhuis, M. H. et al. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. Fam. Cancer 13, 57-63 (2014).
36. Tan, M. H. et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin. Cancer Res. 18, 400-407 (2012).
37. Bubien, V. et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J. Med. Genet. 50, 255-263 (2013).
38. Nieuwenhuis, M. H. et al. Is colorectal surveillance indicated in patients with PTEN mutations? Colorectal Dis. 14, 562-566 (2012).
39. Squarize, C. H., Castilho, R. M. & Gutkind, J. S. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res. 68, 7066-7072 (2008).
40. Jaeger, E. et al. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat. Genet. 44, 699-703 (2012).
41. Cao, X. et al. Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23 by genomewide high-density single nucleotide polymorphism (SNP) scan and identification of BMPR1A loss of function. J. Med. Genet. 43, e13 (2006).
42. Rosty, C. et al. Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics. Am. J. Surg. Pathol. 36, 876-882 (2012).
43. Snover, D. C., Ahnen, D. J., Burt, R. W. & Odze, R. D. in WHO Classification of Tumours of the Digestive System Ch. 8 (ed Bosman F. T. et al.) 160-165 (IARC, 2010).
44. Jasperson, K. W. et al. Serrated polyposis: colonic phenotype, extracolonic features, and familial risk in a large cohort. Dis. Colon Rectum 56, 1211-1216 (2013).
45. Boparai, K. S. et al. Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. Gut 59, 1222-1225 (2010).
46. Win, A. K. et al. Cancer risks for relatives of patients with serrated polyposis. Am. J. Gastroenterol. 107, 770-778 (2012).
47. Hazewinkel, Y. et al. Incidence of colonic neoplasia in patients with serrated polyposis syndrome who undergo annual endoscopic surveillance. Gastroenterology 147, 88-95 (2014).
48. Lynch, H. T. et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin. Genet. 76, 1-18 (2009).
49. Martin-Lopez, J. V. & Fishel, R. The mechanism of mismatch repair and the functional analysis of mismatch repair defects in Lynch syndrome. Fam. Cancer 12, 159-168 (2013).
50. Vasen, H. F., Nagengast, F. M. & Khan, P. M. Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 345, 1183-1184 (1995).
51. Vasen, H. F. et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62, 812-823 (2013).
52. Vasen, H. F. & de Vos tot Nederveen Cappel, W. H. Cancer: Lynch syndrome-how should colorectal cancer be managed? Nat. Rev. Gastroenterol. Hepatol. 8, 184-186 (2011).
53. Burn, J. et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N. Engl. J. Med. 359, 2567-2578 (2008).
54. Burn, J. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378, 2081-2087 (2011).
55. Barrow, E., Hill, J. & Evans, D. G. Cancer risk in Lynch Syndrome. Fam. Cancer 12, 229-240 (2013).
56. ten Broeke, S. W. et al. Lynch syndrome caused by germline PMS2 mutations; delineating the cancer risk. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2014.57.8088.
57. Senter, L. et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135, 419-428 (2008).
58. Baglietto, L. et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J. Natl Cancer. Inst. 102, 193-201 (2010).
59. Engel, C. et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J. Clin. Oncol. 30, 4409-4415 (2012).
60. Vasen, H. F. et al. Guidelines for the clinical management of Lynch syndrome (hereditary nonpolyposis cancer). J. Med. Genet. 44, 353-362 (2007).
61. Barrow, E. et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin. Genet. 75, 141-149 (2009).
62. Grindedal, E. M. et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol. Biomarkers Prev. 18, 2460-2467 (2009).
63. Ligtenberg, M. J. et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat. Genet. 41, 112-117 (2009).
64. Kovacs, M. E., Papp, J., Szentirmay, Z., Otto, S. & Olah, E. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum. Mutat. 30, 197-203 (2009).
65. Ligtenberg, M. J., Kuiper, R. P., Geurts van, K. A. & Hoogerbrugge, N. EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Fam. Cancer 12, 169-174 (2013).
66. Kempers, M. J. et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 12, 49-55 (2011).
67. Ramsoekh, D. et al. A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting. Gut 57, 1539-1544 (2008).
68. Hendriks, Y. M. et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127, 17-25 (2004).
69. Mensenkamp, A. R. et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndromelike tumors. Gastroenterology 146, 643-646 (2014).
70. Lindor, N. M. et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293, 1979-1985 (2005).
71. Mesher, D. et al. A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer. Int. J. Cancer 134, 939-947 (2014).
72. Dove-Edwin, I. et al. Prospective results of surveillance colonoscopy in dominant familial colorectal cancer with and without Lynch syndrome. Gastroenterology 130, 1995-2000 (2006).
73. Hampel, H. et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N. Engl. J. Med. 352, 1851-1860 (2005).
74. Vasen, H. F., Mecklin, J. P., Khan, P. M. & Lynch, H. T. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis. Colon Rectum 34, 424-425 (1991).
75. Vasen, H. F., Watson, P., Mecklin, J. P. & Lynch, H. T. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116, 1453-1456 (1999).
76. Park, J. G. et al. Suspected hereditary nonpolyposis colorectal cancer: International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) criteria and results of genetic diagnosis. Dis. Colon Rectum 42, 710-715 (1999).
77. Rodriguez-Bigas, M. A. et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J. Natl Cancer Inst. 89, 1758-1762 (1997).
78. Boland, C. R. et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248-5257 (1998).
79. Pinol, V. et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293, 1986-1994 (2005).
80. Kastrinos, F., Balmana, J. & Syngal, S. Prediction models in Lynch syndrome. Fam. Cancer 12, 217-228 (2013).
81. Balaguer, F. et al. Validation and extension of the PREMM1, 2 model in a population-based cohort of colorectal cancer patients. Gastroenterology 134, 39-46 (2008).
82. van Dijk, D. A., Oostindier, M. J., Kloosterman-Boele, W. M., Krijnen, P. & Vasen, H. F. Family history is neglected in the work-up of patients with colorectal cancer: a quality assessment using cancer registry data. Fam. Cancer 6, 131-134 (2007).
83. Vasen, H. F. et al. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam. Cancer 9, 109-115 (2010).
84. Hampel, H. & de la Chapelle, A. How do we approach the goal of identifying everybody with Lynch syndrome? Fam. Cancer 12, 313-317 (2013).